Clinical Trial Update: BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating BBP-398 in combination with Osimertinib for locally advanced or metastatic non-small cell lung cancer with EGFR mutations has been term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BBP-398
• Osimertinib (osimertinib)

Snippet

Sponsor: LianBio LLC | Conditions: NSCLC | Phase 1 | Status: TERMINATED